Apollomics vs Immunome
APLM and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How APLM and IMNM compare
Immunome scores higher on the StockData Score (6 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | APLM | IMNM |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.1B |
| Share price | $17.68 | $18.77 |
| Change, 1 year | 7.0% | 7.7% |
| Change, 5 years | – | 9.1% |
| Beta (5Y) | 0.68 | 1.74 |
| Employees | 14 | 177 |
| StockData Score | ||
| Total score | 0 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 531× |
| P/B | – | 4.7× |
| FCF yield | – | −9.6% |
| Growth | ||
| Revenue growth (TTM) | – | −63.3% |
| Profitability | ||
| Operating margin | – | −5948% |
| Net margin | – | −5594% |
| FCF margin | – | −5119% |
| Return on equity | – | −62.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.96 | 11.66 (better) |
| Altman Z-score | – | 21.85 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 104% |
| Held by insiders | 76.0% | 6.4% |
| Insider net buying, 12 months | $8.3M (better) | −$25.2M |
| Short interest, % of float | – | 15.2% |
Go deeper
- APLM stock overview
- APLM income statement
- APLM valuation and score
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.